SS Innovations International Inc. (NASDAQ: SSII) has achieved a significant milestone with the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the SSi Mantra 3.0 surgical robotic system and represents a major step forward in the adoption of robotic-assisted cardiac procedures in the region.
The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This collaboration underscores the company's commitment to advancing surgical robotics globally. According to a recent company video, Kings Hospital has already completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and proficiency with the SSi Mantra system.
This development matters because it signals the growing global reach of SS Innovations and the increasing acceptance of robotic-assisted surgery in new markets. The successful implementation in Sri Lanka not only expands the company's footprint but also validates the clinical utility and reliability of the SSi Mantra 3.0 system. As more hospitals adopt this technology, it could lead to improved patient outcomes, reduced recovery times, and greater access to minimally invasive cardiac surgery.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. These figures point to rising utilization of the company's installed base and growing demand for its robotic systems. The expansion into Sri Lanka is part of this broader growth trajectory and highlights the potential for further market penetration.
The next major corporate milestone is regulatory expansion. SS Innovations is pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up significant opportunities in the world's largest healthcare markets, potentially accelerating revenue growth and solidifying the company's position as a key player in the surgical robotics industry.
Investors and industry observers should note that the launch of the Sri Lankan program is not just a one-off event but a testament to SS Innovations' strategy of targeting underserved markets and demonstrating the versatility of its technology. The company's ability to support complex cardiac procedures in a new environment bodes well for its expansion into other regions. Furthermore, the positive early results at Kings Hospital could serve as a reference for other hospitals considering robotic surgery programs.
For more information about SS Innovations and its latest developments, visit the company's newsroom at https://ibn.fm/SSII. Additionally, details about TechMediaWire's services and disclaimers can be found at https://www.TechMediaWire.com and https://www.TechMediaWire.com/Disclaimer.
As SS Innovations continues to expand its global presence and pursue regulatory approvals, the successful launch in Sri Lanka serves as a promising indicator of the company's potential to revolutionize cardiac surgery worldwide.
